Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1

Journal of Medicinal Chemistry

Volumn 42, Issue 17, 1999, Pages 3203-3209

  Debnath, Asim Kumar ^a   Radigan, Lin ^a   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADS J1; ADS J2; ANTIVIRUS AGENT; GLYCOPROTEIN GP 41; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DETERMINATION; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; VIRUS INHIBITION;

ANTI-HIV AGENTS; CELL FUSION; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NAPHTHALENESULFONATES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 0033607028     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990154t     Document Type: Article

References (53)

1. Carpenter, C. C.; Fischl, M. A.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D. S. M. S.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. J. Am. Med. Assoc. 1998, 280, 78-86.
2. Markowitz, M.; Saag, M.; Powderly, W. G.; Hurley, A. M.; Hsu, A.; Valdes, J. M.; Henry, D.; Sattler, F.; La Marca, A.; Leonard, J. M.; Ho, D. D. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 1995, 333, 1534-1539.
3. Detels, R.; Munoz, A.; McFarlane, G.; Kingsley, L. A.; Margolick, J. B.; Giorgi, J.; Schrager, L. K.; Phair, J.; for the Multicenter AIDS Cohort Study investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. J. Am. Med. Assoc. 1998, 280, 1497-1503.
4. Hogg, R. S.; Rhone, S. A.; Yip, B.; Sherlock, C.; Conway, B.; Schechter, M. T.; O'Shaughnessy, M. V.; Montaner, J. S. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998, 12, 279-284.
5. Hogg, R. S.; Heath, K. V.; Yip, B.; Craib, K. J.; O'Shaughnessy, M. V.; Schechter, M. T.; Montaner, J. S. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J. Am. Med. Assoc. 1998, 279, 450-454.
6. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338, 853-860.
7. Gunthard, H. F.; Wong, J. K.; Ignacio, C. C.; Guatelli, J. C.; Riggs, N. L.; Havlir, D. V.; Richman, D. D. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 1998, 72, 2422-2428.
8. Richman, D. D. Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Adv. Exp. Med. Biol. 1996, 394, 383-395.
9. Wong, J. K.; Gunthard, H. F.; Havlir, D. V.; Zhang, Z. Q.; Haase, A. T.; Ignacio, C. C.; Kwok, S.; Emini, E.; Richman, D. D. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologie correlates of treatment failure. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 12574-12579.
10. Montaner, J. S.; Hogg, R. S.; Weber, A. E.; Anis, A. H.; O'Shaughnessy, M. V.; Schechter, M. T. The costs of triple-drug anti-HIV therapy for adults in the Americas [letter]. J. Am. Med. Assoc. 1998, 279, 1263-1264.
11. Chan, D. C.; Kim, P. S. HIV entry and its inhibition. Cell 1998, 93, 681-684.
12. Hunter, E. In Human retroviruses and AIDS; Korber, B., Foley, B., Leitner, T., McCutchan, F., Hahn, B., Mellors, J. W., Myers, G., Kuiker, C., Eds.; Los Alamos National Laboratory: Los Alamos, NM, 1997; pp III-55-III-73.
13. Moore, J. P.; Jameson, B. A.; Weiss, R. A.; Sattentau, Q. J. In Viral Fusion Mechanisms; Bentz, J., Ed.; CRC Press: Boca Raton, FL, 1992; pp 233-289.
14. Berger, E. A. HIV entry and tropism: the chemokine receptor connection. AIDS 1997, 11 (Suppl. A), 3-16.
15. Bernstein, H. B.; Tucker, S. P.; Kar, S. R.; McPherson, S. A.; McPherson, D. T.; Dubay, J. W.; Lebowitz, J.; Compans, R. W.; Hunter, E. Oligomerization of the hydrophobic heptad repeat of gp41. J. Virol. 1995, 69, 2745-2750.
16. Poumbourios, P.; Wilson, K. A.; Center, R. J.; El Ahmar, R.; Kemp, B. E. Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence. J. Virol. 1997, 71, 2041-2049.
17. Caffrey, M.; Cai, M.; Kaufman, J.; Stahl, S. J.; Wingfield, P. T.; Covell, D. G.; Gronenborn, A. M.; Clore, G. M. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 1998, 17, 4572-4584.
18. Wild, C.; Oas, T.; McDanal, C.; Bolognesi, D.; Matthews, T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10537-10541.
19. Lu, M.; Kim, P. S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 1997, 15, 465-471.
20. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. HIV-1 inhibition by a peptide. Nature 1993, 365, 113.
21. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9770-9774.
22. Lu, M.; Blacklow, S. C.; Kim, P. S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nature Struct. Biol. 1995, 2, 1075-1082.
23. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89, 263-273.
24. Weissenhorn, W.; Wharton, S. A.; Calder, L. J.; Earl, P. L.; Moss, B.; Aliprandis, E.; Skehel, J. J.; Wiley, D. C. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rodlike oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J. 1996, 15, 1507-1514.
25. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15613-15617.
26. Jiang, S.; Lin, K.; Lu, M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol. 1998, 72, 10213-10217.
27. Kilby, J. M.; Hopkins, S.; Venetta, T. M.; DiMassimo, B.; Cloud, G. A.; Lee, J. Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; Matthews, T.; Johnson, M. R.; Nowak, M. A.; Shaw, G. M.; Saag, M. S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 1998, 4, 1302-1307.
28. DesJarlais, R. L.; Seibel, G. L.; Kuntz, I. D.; Furth, P. S.; Alvarez, J. C.; Ortiz de Montellano, P. R.; DeCamp, D. L.; Babe, L. M.; Craik, C. S. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6644-6648.
29. Ring, C. S.; Sun, E.; McKerrow, J. H.; Lee, G. K.; Rosenthal, P. J.; Kuntz, I. D.; Cohen, F. E. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 3583-3587.
30. Rutenber, E.; Fauman, E. B.; Keenan, R. J.; Fong, S.; Furth, P. S.; Ortiz de Montellano, P. R.; Meng, E.; Kuntz, I. D.; DeCamp, D. L.; Salto, R.; Rose, J. R.; Craick, C.; Stroud, R. M. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. J. Biol. Chem. 1993, 268, 15343-15346.
31. Shoichet, B. K.; Stroud, R. M.; Santi, D. V.; Kuntz, I. D.; Perry, K. M. Structure-based discovery of inhibitors of thymidylate synthase. Science 1993, 259, 1445-1450.
32. Bodian, D. L.; Yamasaki, R. B.; Buswell, R. L.; Stearns, J. F.; White, J. M.; Kuntz, I. D. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993, 32, 2967-2978.
33. DesJarlais, R. L.; Sheridan, R. P.; Seibel, G. L.; Dixon, J. S.; Kuntz, I. D.; Venkataraghavan, R. Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J. Med. Chem. 1988, 31, 722-729.
34. Shoichet, B. K.; Bodian, D. L.; Kuntz, I. D. Molecular docking using shape descriptors. J. Comput. Chem. 1992, 13, 380-397.
35. SYBYL 6.5, Tripos Inc., 1699 S. Hanley Rd., St. Louis, MO 63144.
36. CrystalEyes, Stereographic Corp., 2171 E. Francisco Blvd, San Rafel, CA 94901.
37. Pearlman, R. S. CONCORD 4.0 User's Manual; Tripos Inc.: St. Louis, MO, 1998.
38. Jiang, S.; Lin, K.; Zhang, L.; Debnath, A. K. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Viral. Methods 1999, 80, 85-96.
39. Jiang, S.; Lin, K.; Neurath, A. R. Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 1991, 174, 1557-1563.
40. Chou, T.-C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy; Chou, T.-C., Rideout, D. C., Eds.; Academic Press: San Diego, CA, 1991; pp 61-102.
41. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41. Biochem. Biophys. Res. Commun. 1993, 195, 533-538.
42. Lebl, M. Parallel personal comments on "classical" papers in combinatorial chemistry J. Comb. Chem. 1999, 1, 3-24.
43. Kubinyi, H. Strategies and recent technologies in drug discovery. Pharmazie 1995, 50, 647-662.
44. Bevan, P.; Ryder, H.; Shaw, I. Identifying small-molecule lead compounds: the screening approach to drug discovery. Trends Biotechnol. 1995, 13, 115-121.
45. Selzer, P. M.; Chen, X.; Chan, V. J.; Cheng, M.; Kenyon, G. L.; Kuntz, I. D.; Sakanari, J. A.; Cohen, F. E.; McKerrow, J. H. Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp. Parasitol. 1997, 87, 212-221.
46. Chen, Q.; Shafer, R. H.; Kuntz, I. D. Structure-based discovery of ligands targeted to the RNA double helix, Biochemistry 1997, 36, 11402-11407.
47. Good, A. C.; Ewing, T. J.; Gschwend, D. A.; Kuntz, I. D. New molecular shape descriptors: application in database screening. J. Comput.-Aided Mol. Des. 1995, 9, 1-12.
48. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-1082.
49. Gschwend, D. A.; Sirawaraporn, W.; Santi, D. V.; Kuntz, I. D. Specificity in structure-based drug design: Identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase. Proteins 1997, 29, 59-67.
50. De Clercq, E. New acquisitions in the development of anti-HIV agents. Antiviral Res. 1989, 12, 1-19.
51. Baba, M.; Schols, D.; Pauwels, R.; Balzarini, J.; De Clercq, E. Fuschin acid selectively inhibits human immunodeficiency virus (HIV) replication in vitro. Biochem. Biophys. Res. Commun. 1988, 155, 1404-1411.
52. Schols, D.; Pauwels, R.; Desmyter, J.; De Clercq, E. Dextran sulfate and other polyionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 1990, 175, 556-561.
53. Weng, Y.; Weiss, C. D. Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 1998, 72, 9676-9682.